138 related articles for article (PubMed ID: 24053208)
1. Recurrent or refractory primary central nervous lymphoma: therapeutic considerations.
Dahiya S; Murphy ES; Chao ST; Stevens GH; Peereboom DM; Ahluwalia MS
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1109-19. PubMed ID: 24053208
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
3. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma.
Gerstner ER; Batchelor TT
Arch Neurol; 2010 Mar; 67(3):291-7. PubMed ID: 20212226
[TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphoma: overview of current treatment strategies.
Brastianos PK; Batchelor TT
Hematol Oncol Clin North Am; 2012 Aug; 26(4):897-916. PubMed ID: 22794289
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma.
Ferreri AJ; Reni M
Crit Rev Oncol Hematol; 2007 Sep; 63(3):257-68. PubMed ID: 17590348
[TBL] [Abstract][Full Text] [Related]
7. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
8. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria.
Siegal T
J Clin Neurosci; 2014 May; 21(5):709-15. PubMed ID: 24725453
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma in the elderly: the Cleveland clinic experience.
Xie H; Dahiya S; Murphy ES; Chao ST; Suh JH; Stevens GH; Peereboom DM; Ahluwalia MS
Anticancer Res; 2013 Aug; 33(8):3251-8. PubMed ID: 23898087
[TBL] [Abstract][Full Text] [Related]
12. Primary central nervous system lymphoma.
Batchelor TT
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):379-385. PubMed ID: 27913504
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Raizer JJ; Rademaker A; Evens AM; Rice L; Schwartz M; Chandler JP; Getch CC; Tellez C; Grimm SA
Cancer; 2012 Aug; 118(15):3743-8. PubMed ID: 22179954
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
Provencher S; Ferlay C; Alaoui-Slimani K; Devidas A; Lepretre S; de Prijck B; Sebban C; de la Fouchardiere A; Chassagne-Clement C; Ketterer N; Thyss A; Delannoy A; Tilly H; Biron P; Blay JY; Ghesquières H
Hematol Oncol; 2011 Mar; 29(1):10-6. PubMed ID: 21381074
[TBL] [Abstract][Full Text] [Related]
15. Primary central nervous system lymphoma causing multiple spinal cord compression and carcinomatous meningitis in a 6-year-old: a case report.
Quadri SA; Sobani ZA; Enam SA; Enam K; Ashraf MS
J Pediatr Hematol Oncol; 2011 May; 33(4):312-5. PubMed ID: 21464767
[TBL] [Abstract][Full Text] [Related]
16. Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature.
Selch MT; Shimizu KT; De Salles AF; Sutton C; Parker RG
Am J Clin Oncol; 1994 Aug; 17(4):286-93. PubMed ID: 8048389
[TBL] [Abstract][Full Text] [Related]
17. Second-line treatment for primary central nervous system lymphoma.
Reni M; Ferreri AJ; Villa E
Br J Cancer; 1999 Feb; 79(3-4):530-4. PubMed ID: 10027325
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
Ney DE; Reiner AS; Panageas KS; Brown HS; DeAngelis LM; Abrey LE
Cancer; 2010 Oct; 116(19):4605-12. PubMed ID: 20572045
[TBL] [Abstract][Full Text] [Related]
19. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
Du S; Fu DB; A Bota D; Kong XT
CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma.
Schaff LR; Grommes C
Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
